KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Tax Provisions (2018 - 2025)

Historic Tax Provisions for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $115000.0.

  • Castle Biosciences' Tax Provisions fell 9808.75% to $115000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 23258.94%. This contributed to the annual value of $3.3 million for FY2024, which is 318613.86% up from last year.
  • As of Q3 2025, Castle Biosciences' Tax Provisions stood at $115000.0, which was down 9808.75% from -$4.7 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Tax Provisions peaked at $6.0 million during Q3 2024, and registered a low of -$8.7 million during Q4 2021.
  • Its 5-year average for Tax Provisions is -$754625.0, with a median of $15000.0 in 2023.
  • Its Tax Provisions has fluctuated over the past 5 years, first crashed by 3924000.0% in 2022, then soared by 1869062.5% in 2024.
  • Over the past 5 years, Castle Biosciences' Tax Provisions (Quarter) stood at -$8.7 million in 2021, then skyrocketed by 100.65% to $57000.0 in 2022, then plummeted by 31.58% to $39000.0 in 2023, then tumbled by 4471.79% to -$1.7 million in 2024, then skyrocketed by 106.74% to $115000.0 in 2025.
  • Its Tax Provisions stands at $115000.0 for Q3 2025, versus -$4.7 million for Q2 2025 and -$423000.0 for Q1 2025.